Comparative Pharmacology
Head-to-head clinical analysis: FLAGYL versus TINIDAZOLE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FLAGYL versus TINIDAZOLE.
FLAGYL vs TINIDAZOLE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Metronidazole, a nitroimidazole antibiotic, enters bacterial cells and is reduced to cytotoxic intermediates that damage DNA and inhibit nucleic acid synthesis, leading to cell death. It is active against anaerobic bacteria and protozoa.
Tinidazole is a nitroimidazole antibiotic that diffuses into microorganisms where it is reduced by bacterial nitroreductases to form reactive cytotoxic intermediates that damage DNA and inhibit protein synthesis, leading to cell death. It is active against anaerobic bacteria and protozoa.
Metronidazole 500 mg intravenously every 8 hours or 500 mg orally every 8 hours.
2 g orally once daily for 2 days; alternatively, 1 g orally once daily for 5 days for trichomoniasis. For bacterial vaginosis: 2 g orally once daily for 2 days. For giardiasis: 2 g orally as a single dose. For amebiasis: 2 g orally once daily for 3 days for intestinal amebiasis; 2 g orally once daily for 5 days for hepatic amebiasis.
None Documented
None Documented
Clinical Note
moderateTinidazole + Sulfisoxazole
"The metabolism of Sulfisoxazole can be decreased when combined with Tinidazole."
Clinical Note
moderateTinidazole + Erythromycin
"The metabolism of Erythromycin can be decreased when combined with Tinidazole."
Clinical Note
moderateTinidazole + Cyclosporine
"The metabolism of Cyclosporine can be decreased when combined with Tinidazole."
Clinical Note
moderateTinidazole + Fluconazole
Terminal elimination half-life: 6-8 hours in adults with normal renal function; prolonged to 7-21 hours in hepatic impairment; no significant change in renal impairment; clinically relevant for dosing interval (usually 8-hourly).
The terminal elimination half-life is approximately 12-14 hours in healthy adults, which supports once-daily dosing. In hepatic impairment, half-life may be prolonged.
Renal: 60-80% of dose excreted unchanged in urine; biliary/fecal: 6-15% as metabolites and unchanged drug; enterohepatic circulation contributes to prolonged elimination.
Following oral administration, approximately 20-25% of the dose is excreted unchanged in urine, with an additional 10-15% as metabolites. Fecal excretion accounts for about 50% of the dose, primarily as metabolites. Biliary excretion is a minor route.
Category C
Category A/B
Nitroimidazole Antibiotic
Nitroimidazole Antibiotic
"The metabolism of Fluconazole can be decreased when combined with Tinidazole."